Teva eyes $25B in financing for Mylan deal; CA appeals court slaps pharma in pay-for-delay case;

@FiercePharma: Millions more in funding allocated to battle worst avian flu outbreak in U.S. history. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: Big news! FiercePharmaMarketing will now publish every Monday and Wednesday. More | Follow @CarlyHFierce

> Teva Pharmaceutical Industries ($TEVA) is looking for $25 billion in financing to back its proposed takeover of U.S. generics giant Mylan ($MYL). Report

> In a closely watched pay-for-delay case, a California appeals court ruled that a 1997 patent settlement between Bayer and Barr Pharmaceuticals violated state antitrust law. Report

> Novartis ($NVS) is beefing up its presence in Poland with a new packaging center in Stryków. Report

> Abuse of painkillers is fueling the spread of hepatitis C, the Centers for Disease Control and Prevention said in a new report. Report

> Teva shrugged off an opportunity to buy Perrigo ($PRGO), the over-the-counter drug specialist that its own buyout quarry, Mylan, is trying to purchase in defense. Report

Medical Device News

@FierceMedDev: ICYMI: Philips CEO outlines HealthTech vision as shareholders vote to separate lighting biz. Story | Follow @FierceMedDev

@VarunSaxena2: Concordia running trials to expand use of its laser-activated cancer-fighting drug. FierceDrugDelivery article | Follow @VarunSaxena2

@EmilyWFierce: Novartis grabs Zykadia approval in Europe, setting the stage for PD-L1 showdown. ICYMI from FiercePharma | Follow @EmilyWFierce

> Bayer responds to article critical of its Essure birth control device under FDA investigation. More

> In a move toward an artificial pancreas, Debiotech gains option for Bayer's iSense CGM. Story

> FDA approves Nevro device that eliminates side effect of spinal stimulation. Article

Biotech News

@FierceBiotech: ICYMI Friday: EuroBiotech Report: $ABBV orders $30M of Galapagos' IPO, Indivior aces schizophrenia trial, $GILD inks Danish deal. More | Follow @FierceBiotech

@JohnCFierce: Hey, $GSK. Hyping a tiny, discovery-stage biotech as a quest for an HIV cure smells of desperation. News | Follow @JohnCFierce

> Amgen, Fidelity help bankroll another upstart gene-editing player with $27M A round. Story

> Celgene's R&D speed dating is starting to pay off, CEO says. Article

> Actavis keeps its Phase III promise with Molecular Partners' eye drug. More

Animal Health News

> Millions more in funding allocated to battle worst avian influenza outbreak in U.S. history. Report

> Trupanion reports Q1 loss as marketing spend kicks into high gear. Item

> Mars Petcare forms new alliance to expand use of DNA testing in vet hospitals. More

> Aratana tops estimates as Q1 loss narrows. Article

> Zoetis CEO on cost-cutting push: 'We will be much more focused.' Story

Biotech IT News

> SFW Capital Partners closes $345M analytical tools fund. News

> Pfizer, 23andMe start building 5,000-person lupus database. More

> Agilent bolsters presence in clinical lab software sector with Cartagenia buyout. Report

> Medidata links its cloud platform to Apple's ResearchKit. Story

> Buzz: Apple plans to add 23andMe-style spit kits to ResearchKit studies. Article

Pharma Marketing News

> AdverseEvents: New generation of hep C meds bests older therapies in side-effect reports. More

> Secret doctor letter shows Amarin's true 'free speech' leanings. Article

> That Namenda hard switch Actavis wants? It could cost HHS $6B. Item

> Back-to-'Biogen' shift signals wider industry branding trend. News

> Is there a place for pharma in the emerging EHR market? More

And Finally ... A drug-resistant form of typhoid is spreading worldwide. Report

Suggested Articles

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.

Weeks after launching a U.S. trial to evaluate IL-6 inhibitor Kevzara for COVID-19, Sanofi and Regeneron have launched a matching study abroad.